← All trials
NCT04171284
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2019
- Primary completion
- Oct 22, 2022
- Completion date
- May 22, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 360
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sinocelltech Ltd.Lead sponsor
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.